brexpiprazole / Generic mfg. - LARVOL DELTA

Rational antipsychotic polypharmacy in psychotic and bipolar disorders: A focus on D2 receptor partial agonists. (PubMed, Ment Health Clin) - "Aripiprazole, brexpiprazole, and cariprazine have a unique pharmacology as demonstrated by their high affinity to the dopamine type-2 receptor (ie, D2 receptor). Some partial agonists may be less preferred in particular patient scenarios based on their demonstrated clinical efficacy. Three illustrative patient cases highlight clinical pearls related to the safe and effective use of antipsychotic polypharmacy involving partial agonist antipsychotics."

Journal • Anesthesia • Bipolar Disorder • CNS Disorders • Mood Disorders • Movement Disorders • Psychiatry

Comparative efficacy and safety of different brexpiprazole doses for agitation in Alzheimer's disease: A systematic review and network meta-analysis. (PubMed, J Alzheimers Dis) - "The findings support initiating treatment at lower doses with careful titration to 2 mg based on individual response and tolerability. Future research should focus on long-term outcomes and real-world effectiveness."

Journal • Retrospective data • Review • Alzheimer's Disease • CNS Disorders • Psychiatry

Bioequivalence Study to Compare Brexpiprazole 4 mg Film Coated Tablets Versus RXULTI 4 mg Film Coated Tablet (Brexpiprazole) (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Humanis Saglık Anonim Sirketi

New P1 trial • CNS Disorders • Psychiatry • Schizophrenia

Lack of Generalizability of PTSD Treatment Trials: The Recent Brexpiprazole-Sertraline Trials as an Example. (PubMed, J Clin Psychiatry) - "As a result, we remain uncertain about the medications' effectiveness for most patients treated in clinical practice. We urge regulatory agencies to require industry to conduct studies that better reflect the patient populations seen in clinical practice."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry

Managing Symptoms in Adolescent-Onset Schizophrenia: A Narrative Review of Therapeutic Interventions. (PubMed, Healthcare (Basel)) - "Synthesis of this evidence highlights atypical antipsychotics such as aripiprazole and brexpiprazole as well-tolerated first-line options for positive symptom reduction, while clozapine remains the most effective treatment for resistant AOS. High-dose olanzapine offers comparable efficacy but carries greater metabolic risk...Collectively, these findings highlight the importance of early, developmentally informed, and multidisciplinary interventions tailored to adolescents. Strengthening longitudinal, biomarker-guided, and neuromodulation-inclusive studies will be critical for refining precision treatment models and informing future clinical and policy frameworks for adolescent psychosis care."

Journal • Review • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia • CCL11 • IL6

Patient Life Engagement and Metabolic Profile Improve After Switching from First-/Second-Generation Antipsychotics to Brexpiprazole: A Real-World Study in Patients with Schizophrenia. (PubMed, J Pers Med) - " Switching to brexpiprazole was associated with improvements in psychopathological, functional, and physical health domains. These findings support its potential role in real-world, personalized therapeutic strategies for patients with schizophrenia following suboptimal outcomes with prior antipsychotic treatments."

Journal • Real-world evidence • CNS Disorders • Psychiatry • Schizophrenia

Comparative Efficacy and Tolerability of Multiple Antipsychotics Across Varying Doses for Neuropsychiatric Symptoms of Dementia Including Alzheimer's Disease: A Dose-Response Model-Based Network Meta-Analysis. (PubMed, Acta Psychiatr Scand) - "Aripiprazole 10 mg, brexpiprazole 1-2.5 mg, risperidone 1 mg, and olanzapine 2.5 mg were both effective and well tolerated, indicating their potential as favorable treatment options. As the present model incorporates several sources of uncertainty, its findings should be interpreted with caution and regarded as a provisional framework to support clinical decision-making."

Journal • Retrospective data • Review • Alzheimer's Disease • CNS Disorders • Dementia • Psychiatry

A Sustainable Photochemical Strategy Based on a "Fluorescence On-Off" Mode for Nanoscale-Quantitative Analysis of Brexpiprazole in Different Matrices: Tablet Uniformity Evaluation. (PubMed, Luminescence) - "Additionally, its overall "whiteness" and "blueness" were evaluated using the innovative RGB12 and BAGI ranking systems. This multifaceted approach not only ensures precise BXZ quantification but also establishes a new benchmark for sustainable analytical chemistry in pharmaceutical research and quality control."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Agitation (PubMed, Brain Nerve) - "Brexpiprazole has been approved as effective for agitation in Alzheimer's disease. For the treatment of agitation, medications other than brexpiprazole are frequently used in clinical settings and may offer some degree of efficacy."

Journal • Alzheimer's Disease • CNS Disorders • Dementia

Brexpiprazole does not adversely impact neurobehavior following preclinical traumatic brain injury (Neuroscience 2025) - "Contrary to our hypothesis, brexpiprazole did not improve outcomes relative to vehicle (p>0.05), but it also did not worsen. This finding suggests that brexpiprazole may be a safer option for managing TBI-induced agitation without the negative cognitive effects associated with traditional APDs with D2 antagonist actions like haloperidol and risperidone."

Preclinical • CNS Disorders • Vascular Neurology

Comparative Prevalence of Suicidal Ideation and Self-Harm History: Rexulti vs. Other Oral Atypical Antipsychotics (ISPOR-EU 2025) - "Results show that brexpiprazole was associated with significantly lower rates of suicidal ideation/self-harm in patients with MDD vs other AAPs. Additional studies are needed to understand the underlying mechanisms and validate these findings across broader populations. These results offer important guidance for clinicians selecting antipsychotic treatments for patients with MDD."

CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Suicidal Ideation

A Systematic Literature Review of Economic Evaluation Studies for Schizophrenia (ISPOR-EU 2025) - "SGAs such as olanzapine, paliperidone, and clozapine were frequently associated with improved relapse prevention and reduced inpatient costs, contributing to favorable cost-effectiveness profiles compared to haloperidol or other FGAs. Newer agents, including lurasidone and brexpiprazole, appeared in a limited number of recent studies... This review reinforces the long-term value of schizophrenia interventions, particularly SGAs, and underscores the need for consistent methodological standards. These findings contribute to a more robust evidence base for HTA submissions, inform pricing and reimbursement decisions, and support the development of sustainable, value-based mental health policies."

HEOR • Review • CNS Disorders • Psychiatry • Schizophrenia

Brexpiprazole for Managing Mania After Methylprednisolone Pulse Therapy in a Patient With Adult-Onset Still Disease. (PubMed, Am J Ther) - No abstract available

Journal • Bipolar Disorder • CNS Disorders • Immunology • Mood Disorders

Distinct functional profiles of partial agonist antipsychotics in cAMP and β-arrestin signaling mechanisms of dopamine D2 and D3 receptors in vitro. (PubMed, Prog Neuropsychopharmacol Biol Psychiatry) - "While cariprazine showed partial agonism and partial antagonism at D3 receptor-mediated β-arrestin translocation, aripiprazole and brexpiprazole displayed only weak or no agonist but potent antagonist activity. These data suggest differentiated mechanism of action of cariprazine at the D3 receptor signaling compared to aripiprazole and brexpiprazole."

Journal • Preclinical • CNS Disorders

Impact of selected second and third generation antipsychotics on cognitive dysfunction in schizophrenia-spectrum disorders. Systematic review and network meta-analysis. (PubMed, Int Clin Psychopharmacol) - "This study aimed to: (a) systematically review randomized controlled trials (RCTs) evaluating the cognitive effects of third-generation antipsychotics (TGAs: brexpiprazole, cariprazine, lumateperone, and lurasidone) and xanomeline-trospium; and (b) perform a network meta-analysis (NMA) including additional second-generation antipsychotics with potential procognitive effects. A systematic literature search identified eligible RCTs, which were combined with trials on aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone from a previous meta-analysis...In conclusion, selected second and TGAs, including M1/M4 receptor agonists such as xanomeline, may offer promising treatment options for cognitive dysfunction. Further research should personalize pharmacological strategies based on cognitive profiles."

Journal • Retrospective data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Brexpiprazole as a Treatment Option for Risperidone-Resistant Delusional Parasitosis. (PubMed, Am J Ther) - No abstract available

Journal

Brexpiprazole-Induced Rhabdomyolysis and Extrapyramidal Symptoms in an Alzheimer Dementia Patient on Rivastigmine. (PubMed, Am J Ther) - No abstract available

Journal • Alzheimer's Disease • CNS Disorders • Dementia

Pharmacogenetic Guidelines and Resources to Support Antidepressant and Antipsychotic Use in Child and Adolescent Psychiatry (AACAP 2025) - "The FDA categorizes drug-gene pairs by implications on therapeutic management, safety, or pharmacokinetics. If a patient has genotype results available, the CPIC and/or FDA currently provide assessments supporting the utility of PGx to inform the use of many antidepressants including es/citalopram (CYP2C19), fluvoxamine (CYP2D6), paroxetine (CYP2D6), sertraline (CYP2C19 and CYP2B6), TCAs (CYPC19 and/or CYP2D6), venlafaxine (CYP2D6), and vortioxetine (CYP2D6)...FDA labeling provides specific dosing based on CYP2D6 poor metabolizer genotypes for aripiprazole, brexpiprazole, iloperidone, pimozide, and thioridazine... CPIC and FDA resources are useful for identifying evidence-based PGx information for commonly used antidepressants and antipsychotics. PharmGKB and Sequence2Script support access to foundational literature and the clinical implementation of PGx results.PPC, ADP, APS"

Biomarker • Clinical • CNS Disorders • Psychiatry • CYP19A1 • CYP2C19 • HTR2A • SLC6A4

Efficacy and tolerability of brexpiprazole augmentation of SSRI therapy in PTSD: A systematic review and meta-analysis of randomized controlled trials. (PubMed, J Psychiatr Res) - "Somnolence and weight gain were more frequent, with no changes in metabolic labs. Larger, longer-term RCTs are needed to confirm these findings."

Journal • Retrospective data • Review • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Brexpiprazole for the Treatment of Co-occurring Schizophrenia and Substance Use Disorder: A Multisite, Randomized, Controlled Trial. (PubMed, J Clin Psychiatry) - P4 | " This study suggests that brexpiprazole might be beneficial in reducing substance craving and use in patients with schizophrenia and co-occurring substance use disorder; this potential benefit may help improve quality of life and overall psychiatric symptoms in a difficult-to-treat patient population. Trial Registration: ClinicalTrials.gov identifier: NCT03526354."

Clinical • Journal • CNS Disorders • Psychiatry • Schizophrenia

Drug-Induced Movement Disorders in Elderly Patients with Dementia: A Case Study of Acute Dystonia Following Third-Generation Antipsychotic Use (MDS Congress 2025) - "This case study highlights the occurrence of acute dystonia in a 70-year-old female patient with dementia following the administration of brexpiprazole...The antipsychotic was discontinued, and treatment was switched to amantadine sulfate 500 mg IV for 3 days, followed by oral tabs 100-100-0 mg daily... This case underscores the potential for TGA to induce acute dystonia in elderly patients with dementia, despite their reputation for fewer motor side effects. The patient's advanced age, underlying cerebral atrophy, and dementia likely contributed to her heightened susceptibility to DIMDs. Clinicians should remain vigilant for motor side effects, even with newer antipsychotics, and be prepared to intervene promptly."

Case study • Clinical • Alzheimer's Disease • CNS Disorders • Dementia • Dystonia • Frontotemporal Lobar Degeneration • Mood Disorders • Movement Disorders • Psychiatry

EFFECTS OF BREXPIPRAZOLE TREATMENT ON EXTRAPYRAMIDAL AND COGNITIVE SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE (WCN 2025) - "Our "real world study" showed that brexpiprazole is effective in reducing psychotic symptoms and does not affect extrapyramidal symptoms and the cognitive deficits in Parkinson's disease."

Clinical • CNS Disorders • Cognitive Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

A network meta-analysis of the efficacy, safety, and tolerability of xanomeline and trospium chloride versus eight atypical antipsychotics in schizophrenia (ECNP 2025) - P2, P3 | "Xanomeline/trospium treatment significantly improved odds of clinical response versus aripiprazole (odds ratio [OR]: 1.85; 95% credible interval [CrI]: 1.11, 3.11), brexpiprazole (OR: 2.23; 95% CrI: 1.34, 3.83), and cariprazine (OR: 2.05; 95% CrI: 1.19, 3.57), increased odds of all-cause discontinuation versus all comparators except cariprazine, and reduced odds of clinically significant weight gain versus aripiprazole, brexpiprazole, cariprazine, lumateperone, olanzapine, quetiapine, and risperidone. Additional favorable results for xanomeline/trospium included improvements in CFB CGI-S versus aripiprazole, brexpiprazole, cariprazine, and olanzapine, CFB PANSS positive symptoms score versus brexpiprazole, and CFB weight versus brexpiprazole, clozapine, olanzapine, quetiapine, and risperidone... The SLR identified 3664 unique references. After initial screening followed by the addition of 114 records identified from other sources, a total of 142 records from 111..."

Retrospective data • CNS Disorders • Psychiatry • Schizophrenia • DRD2

Brexpiprazole monotherapy and adjunctive brexpiprazole with sertraline for the treatment of post-traumatic stress disorder: a systematic review (ECNP 2025) - "Nonetheless, these findings should be interpreted cautiosly, given the modest sample sizes, limited demographic diversity, and lack of objective biomarkers. Further large-scale, longitudinal studies integrating neuroimaging techniques and stratified sampling are needed to substantiate the clinical efficacy and clarify the mechanistic contributions of brexpiprazole in the treatment of PTSD."

Monotherapy • Review • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry • BDNF

Efficacy and safety of brexpiprazole in early-episode schizophrenia: post hoc analysis of clinical trials in adults and adolescents (ECNP 2025) - P3 | "For the trials in adults, patients aged 18–65 were randomised to placebo (total N=531), brexpiprazole (total N=1,093; 0.25, 1, 2 or 4 mg/day, or 2–4 mg/day, depending on the trial), or quetiapine extended-release (N=154; active reference in one trial). For the trial in adolescents, patients aged 13–17 were randomised to placebo (N=104), brexpiprazole 2–4 mg/day (N=110), or aripiprazole (N=102; active reference)... In this post hoc analysis of patients with early-episode schizophrenia, brexpiprazole was associated with greater improvement in schizophrenia symptoms than placebo. No new safety observations were made. Data previously presented at the 33rd European Congress of Psychiatry (EPA), 5–8 April 2025, Madrid, Spain."

Clinical • Retrospective data • CNS Disorders • Psychiatry • Schizophrenia